ASX:EX1

Exopharm Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive EX1 News and Ratings via Email

Sign-up to receive the latest news and ratings for Exopharm and its competitors with MarketBeat's FREE daily newsletter.

About Exopharm

Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing NaÃ¯ve EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.

Shareholders Are Thrilled That The Exopharm (ASX:EX1) Share Price Increased 173%
March 12, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:EX1
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.exopharm.com
Phone: 61 3 9111 0026
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $4.19 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 3.39
Book Value: A$0.12 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 7.19
Current Ratio: 9.73
Quick Ratio: 9.53

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.96 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Exopharm.

4.8 Community Rank

Outperform Votes
Exopharm has received 8 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Exopharm has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Exopharm has received 72.73% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Exopharm and other stocks. Vote “Outperform” if you believe EX1 will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EX1 will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Exopharm does not currently pay a dividend.
Dividend Growth
Exopharm does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exopharm insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Exopharm (ASX:EX1) Frequently Asked Questions

What stocks does MarketBeat like better than Exopharm?: Wall Street analysts have given Exopharm a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Exopharm wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
Who are Exopharm's key executives?: Exopharm's management team includes the following people:
Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D., Company Founder, Technology Co-Founder, MD & Director
Dr. Gregor Lichtfuss M.Sc., Co-Founder & Bus. Services Mang.
Dr. Christopher Baldwin Ph.D., Deputy CEO & Chief Commercial Officer
Ms. Elizabeth McGregor B.A., M.B.A., Company Sec. & Non-Exec. Director
Who are some of Exopharm's key competitors?: Some companies that are related to Exopharm include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of EX1's competitors.
What is Exopharm's stock symbol?: Exopharm trades on the ASX under the ticker symbol "EX1."
How much money does Exopharm make?: Exopharm has a market capitalization of $0.00 and generates $4.19 million in revenue each year.
How many employees does Exopharm have?: Exopharm employs 41 workers across the globe.
What is Exopharm's official website?: The official website for Exopharm is www.exopharm.com.
How can I contact Exopharm?: The company can be reached via phone at 61 3 9111 0026.

This page was last updated on 10/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.